Epitope base editing: Non-malignant stem cells are going undercover
Cell Stem Cell. 2023 Nov 2;30(11):1400-1402. doi: 10.1016/j.stem.2023.09.009.ABSTRACTEngineered hematopoietic stem cells can be shielded from targeted immunotherapy. Recently published in Nature, Casirati et al. utilized single-base editing of epitopes implicated in acute myeloid leukemia and healthy hematopoiesis to alter their antibody and chimeric antigen receptor (CAR) T recognition while preserving their ligand binding and enzymatic function.PMID:37922877 | DOI:10.1016/j.stem.2023.09.009
Source: Cell Stem Cell - Category: Stem Cells Authors: Shayan Saniei Elvin Wagenblast Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Immunotherapy | Leukemia | Stem Cell Therapy | Stem Cells